Added to YB: 2024-09-17
Pitch date: 2024-09-17
AADI [bullish]
Whitehawk Therapeutics, Inc.
+64.86%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.
Market Cap
$138.6M
Pitch Price
$1.85
Price Target
5.70 (+87%)
Dividend
N/A
EV/EBITDA
0.22
P/E
-9.49
EV/Sales
-1.67
Sector
Biotechnology
Category
value
Show full summary:
Aadi Bioscience: Net Cash, and EU Expansion Could Unlock Upside
AADI: Trading at $1.86, NAV $5.71 ($2.53 net cash + $3.18 FYARRO cash 2025-2028). Potential $7.92 with EU sales. 80% R&D cut, 34 employees left. $24M annual FYARRO sales till 2029 ODD expiry. 206% upside, company for sale. PEComa treatment, BMS licensed, 53-month median survival.
Read full article (3 min)